Engineering of Escherichia coli for targeted delivery of transgenes to HER2/neu-positive tumor cells

Biotechnol Bioeng. 2011 Jul;108(7):1662-72. doi: 10.1002/bit.23095. Epub 2011 Feb 24.

Abstract

Targeting of non-phagocytic tumor cells and prompt release of gene cargos upon entry into tumors are two limiting steps in the bacterial gene delivery path. To tackle these problems, the non-pathogenic Escherichia coli strain BL21(DE3) was engineered to display the anti-HER2/neu affibody on the surface. After co-incubation with tumor cells for 3 h, the anti-HER2/neu affibody-presenting E. coli strain was selectively internalized into HER2/neu-positive SKBR-3 cells. The invasion efficiency reached as high as 30%. Furthermore, the bacteria were equipped with the phage ϕX174 lysin gene E-mediated autolysis system. Carrying the transgene (e.g., eukaryotic green fluorescent protein, GFP), the tumor-targeting bacteria were subjected to the thermal shock to trigger the autolysis system upon entry into HER2/neu-positive cells. Flow cytometric analysis revealed that 3% of infected cells expressed GFP 24 h post thermal induction. Overall, the results show a promise of the proposed approach for developing bacteria as a delivery carrier.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies / immunology
  • Antibodies / metabolism
  • Cell Adhesion
  • Cell Line, Tumor
  • Escherichia coli / genetics*
  • Escherichia coli / physiology*
  • Gene Transfer Techniques*
  • Gene Transfer, Horizontal*
  • Humans
  • Protein Binding
  • Receptor, ErbB-2 / immunology
  • Receptor, ErbB-2 / metabolism
  • Transgenes*

Substances

  • Antibodies
  • ERBB2 protein, human
  • Receptor, ErbB-2